C16-PAF

• UNSPSC Description:

  C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability[1][2][3][4][5].

• Target Antigen:

  Endogenous Metabolite; ERK; MEK; p38 MAPK

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway;Metabolic Enzyme/Protease;Stem Cell/Wnt

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/c16-paf.html

• Purity:

  99.85

• Solubility:

  DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 33.33 mg/mL (ultrasonic)

• Smiles:

  CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(OCC[N+](C)(C)C)([O-])=O

• Molecular Weight:

  523.68

• References & Citations:

  [1]Scott D Ryan, et al. Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons. J Lipid Res. 2008 Oct;49(10):2250-8.|[2]Z Honda, et al. Transfected platelet-activating factor receptor activates mitogen-activated protein (MAP) kinase and MAP kinase kinase in Chinese hamster ovary cells. J Biol Chem. 1994 Jan 21;269(3):2307-15.|[3]Muhammad S Riaz, et al. Direct Growth Inhibitory Effect of Platelet Activating Factor C-16 and Its Structural Analogs on Mycobacteria. Front Microbiol. 2018 Sep 11;9:1903.|[4]Jing Chu, et al. IGHG1 Regulates Prostate Cancer Growth via the MEK/ERK/c-Myc Pathway. Biomed Res Int. 2019 Jul 4;2019:7201562.|[5]Nina Bögershausen, et al. RAP1-mediated MEK/ERK pathway defects in Kabuki syndrome. J Clin Invest. 2015 Sep;125(9):3585-99.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, stored under nitrogen)

• Clinical Information:

  No Development Reported

• CAS Number:

  74389-68-7